Stock Information
symbol line chart

JNJJohnson & Johnson

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Joaquin Duato

Location

New Jersey, USA

Exchange

NYSE

Website

https://jnj.com

Summary

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide.

Company Info

CEO

Joaquin Duato

Location

New Jersey, USA

Exchange

NYSE

Website

https://jnj.com

Summary

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide.

AI Insights for JNJ
5 min read

Quick Summary

Johnson & Johnson is a global healthcare company headquartered in New Brunswick, New Jersey, and led by CEO Joaquin Duato. The company researches, develops, manufactures, and sells healthcare products across innovative medicines and medical technology. Its pharmaceutical business serves patients and healthcare systems with treatments for immunology, oncology, neuroscience, infectious disease, pulmonary hypertension, and other specialty areas. Its MedTech business sells devices and procedural technologies to hospitals, surgeons, cardiologists, electrophysiologists, orthopedists, and other healthcare providers. After the Kenvue consumer-health separation, Johnson & Johnson is more focused on higher-value prescription medicines and medical devices rather than lower-growth consumer brands.

Strengths

•

Johnson & Johnson’s main strength is its scale as one of the largest and most diversified healthcare companies in the world.

•

It has powerful brands, deep physician relationships, global distribution, strong regulatory expertise, and broad capabilities across pharmaceuticals and medical technology.

•

The company’s balance sheet reputation, recurring cash flow, and long dividend history make it attractive to conservative and income-focused investors.

•

Its pipeline includes important potential growth drivers in oncology, immunology, and neuroscience, while its MedTech business benefits from aging populations and rising demand for medical procedures.

•

J&J also has strategic flexibility to fund acquisitions, invest heavily in research and development, and reshape its portfolio through divestitures or spin-offs.

Key Risks

•

Johnson & Johnson faces legal and regulatory risks, including talc litigation, drug-pricing pressure, product-liability claims, and ongoing scrutiny from healthcare authorities.

•

Patent expirations and generic or biosimilar competition could reduce sales and margins for key medicines, especially if pipeline launches fail to scale quickly enough.

•

Macroeconomic and geopolitical risks include foreign-exchange headwinds, tariffs, supply-chain disruption, and weaker demand in markets such as China.

•

Acquisition risk is also meaningful because large deals funded with debt can pressure leverage, integration capacity, and future capital returns if expected revenue synergies do not materialize.

What to Watch

During the most recent supplied quarter, Johnson & Johnson reported substantial operating scale with about $25.31 billion in total revenue and about $17.26 billion in gross profit.
The company generated about $7.14 billion in operating income and about $5.53 billion in net income, indicating continued profitability across its healthcare portfolio.
Recent company news emphasized strength in innovative medicine and medtech, including growth from cancer drugs such as Darzalex and progress in pipeline assets across immunology, oncology, and neuroscience.
J&J also remained active strategically, with news highlighting the $14.6 billion Intra-Cellular deal, the integration of cardiovascular acquisitions, and plans to spin off DePuy Synthes within 18 to 24 months.
Investor attention during the period also centered on talc litigation, China medtech weakness, Stelara competition, tariff exemptions tied to U.S. drug-pricing concessions, and dividend durability.

Price Drivers

•

Johnson & Johnson’s stock price is driven by earnings growth, revenue trends, dividend reliability, litigation developments, and investor confidence in its drug pipeline.

•

The supplied fundamentals show Q3 2026 revenue of about $25.31 billion, operating income of about $7.14 billion, net income of about $5.53 billion, and diluted EPS of $2.27.

•

Valuation is also important, with the data showing a price-to-earnings ratio near 29.95, price-to-book near 7.41, EV-to-EBITDA near 19.92, and EV-to-revenue near 6.72.

•

Recent news suggests investors are balancing solid healthcare growth and dividend strength against talc litigation, Stelara patent pressure, foreign-exchange headwinds, China medtech softness, and acquisition-related debt.

•

The stock also benefits from defensive healthcare characteristics, a low beta of 0.206, and a dividend yield around 2.02%, which may appeal to income-oriented investors during volatile markets.

Recent News

•

Recent news portrays Johnson & Johnson as a defensive healthcare leader and long-term dividend stock, often compared favorably with income-oriented companies.

•

Reports highlighted that J&J beat sales expectations, delivered solid revenue and EPS growth, and continued benefiting from cancer drugs such as Darzalex.

•

Investors nevertheless reacted cautiously to talc litigation, foreign-exchange pressure, China medtech demand, Stelara generic and pricing pressure, and weaker quarterly EPS dynamics.

•

J&J also agreed to lower some U.S. drug prices in exchange for tariff exemptions, reducing a potential cost risk while raising questions about future pricing power.

•

Additional news focused on the planned DePuy Synthes spin-off, the $14.6 billion Intra-Cellular acquisition, a strong drug pipeline, and the company’s long record of dividend increases.

Market Trends

•

Broader healthcare trends affecting Johnson & Johnson include aging populations, rising chronic disease prevalence, demand for minimally invasive procedures, and increasing global use of specialty medicines.

•

The pharmaceutical industry is also being shaped by patent cliffs, biosimilar competition, drug-pricing negotiations, and payer pressure in the United States and abroad.

•

Medical technology companies are benefiting from procedure recovery and innovation, but they also face hospital cost controls, procurement reform, and competition from specialized device makers.

•

Investors are favoring companies with durable cash flow, dividend reliability, and defensive earnings during periods of macroeconomic uncertainty, which supports J&J’s appeal.

•

At the same time, high valuations, litigation uncertainty, and slower growth versus the broader market can limit upside if investors demand faster earnings acceleration.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on JNJ

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@Ethancollins 2 days ago

Johnson & Johnson Still Has Strong Support, but Valuation Is Worth Watching

Johnson & Johnson Still Has Strong Support, but Valuation Is Worth Watching

Johnson & Johnson has attracted plenty of analyst attention, but I’m looking beyond the ratings before getting too optimistic. The stock has already delivered a strong run, gaining more than 35% year to date, and that makes the current valuation an important part of the conversation.

Some analysts remain positive, with price targets reaching $320, while others are more cautious about how much growth is already reflected in the share price. I also want to see how the company handles MedTech growth, acquisition-related costs, and its upcoming earnings report.

I like the defensive side of healthcare businesses, especially when markets get volatile. But even a quality company can become an expensive investment if expectations get too high. I’m more interested in whether JNJ can keep growing earnings than simply following analyst upgrades.

Would you still consider JNJ at these levels, or would you wait for a better entry point?

avatar
@ProduceCut309 2 weeks ago

I’m Looking Beyond AI for the Next Opportunity

I’m Looking Beyond AI for the Next Opportunity

Everyone’s been chasing AI stocks, but I think healthcare deserves a closer look. As investors question expensive AI valuations, healthcare is gaining attention for its steadier demand, reliable earnings and more attractive valuations. I’m watching , and . For me, this is about finding opportunities beyond the crowded AI trade, not betting against AI entirely. Would you rotate some money into healthcare, or are you still all-in on AI?

avatar
@kewur 3 weeks ago

Overview of the Vanguard S&P 500 Growth ETF (VOOG) and its tech weighting

Overview of the Vanguard S&P 500 Growth ETF (VOOG) and its tech weighting

post thumbnail

www.fool.com

| This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term | The Motley Fool

avatar
@Theta_collctv 3 weeks ago

Defensive ETFs to look at if you want to prep for a pullback

Defensive ETFs to look at if you want to prep for a pullback

post thumbnail

www.fool.com

| If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys | The Motley Fool

avatar
@AlexWalker 1 month ago

Which Dividend Stocks Can Weather a Downturn?

Which Dividend Stocks Can Weather a Downturn?

When the market gets shaky, I like the idea of having businesses that can keep generating cash and paying dividends through the cycle. Healthcare names such as , and stand out because demand for their products doesn’t disappear when the economy slows.

I’m curious, would you rather focus on dividend stability or higher growth during a downturn?

avatar
@BarnaclesActiv 2 months ago

J&J's 13F shows 15 biotech holdings, with Protagonist Therapeutics as their biggest position

J&J's 13F shows 15 biotech holdings, with Protagonist Therapeutics as their biggest position

post thumbnail

www.fool.com

| Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. | The Motley Fool

avatar
@Theta_collctv 2 months ago

Motley Fool's latest healthcare stock recommendations

Motley Fool's latest healthcare stock recommendations

post thumbnail

www.fool.com

| 4 Best Pharmaceutical Stocks for 2026 and How to Invest | The Motley Fool

avatar
@Altruistic_Dr2 3 months ago

Motley Fool biotech and pharma holdings update

Motley Fool biotech and pharma holdings update

post thumbnail

www.fool.com

| Biotechnology vs. Pharmaceuticals: What Are the Differences? | The Motley Fool

avatar
@frostmourne 3 months ago

Healthcare stocks JNJ, UNH, and MCK as defensive dividend plays

Healthcare stocks JNJ, UNH, and MCK as defensive dividend plays

post thumbnail

www.fool.com

| Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night. | The Motley Fool

avatar
@Ethancollins 3 months ago

Dividend stocks are back on investors' watchlists.

Dividend stocks are back on investors' watchlists.

As markets become more volatile, many investors are turning their attention back to dividend-paying companies that can provide a combination of steady income and long-term growth. High-quality dividend stocks have historically helped investors navigate uncertain markets by generating consistent cash flow while still offering the potential for capital appreciation. For long-term portfolios, balancing reliable dividends with business quality remains just as important as chasing the highest yield. If you had to choose today, would you rather own dividend stocks like and , or focus on higher-growth names like and ?